Vimseltinib for tenosynovial giant cell tumour

Hiroshi Urakawa¹, Shiro Imagama²

Affiliations

¹ Department of Advanced Medicine, Nagoya University Hospital, Nagoya 4668560, Japan. Electronic address: urakawa@med.nagoya-u.ac.jp.
² Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

PMID: 38843859
DOI: 10.1016/S0140-6736(24)01113-9

Comment

Vimseltinib for tenosynovial giant cell tumour

Hiroshi Urakawa et al. Lancet. 2024.

. 2024 Jun 22;403(10445):2665-2667.

doi: 10.1016/S0140-6736(24)01113-9. Epub 2024 Jun 3.

Authors

Hiroshi Urakawa¹, Shiro Imagama²

Affiliations

¹ Department of Advanced Medicine, Nagoya University Hospital, Nagoya 4668560, Japan. Electronic address: urakawa@med.nagoya-u.ac.jp.
² Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

PMID: 38843859
DOI: 10.1016/S0140-6736(24)01113-9

Erratum in

Department of Error.
[No authors listed] [No authors listed] Lancet. 2024 Jun 29;403(10446):2786. doi: 10.1016/S0140-6736(24)01180-2. Epub 2024 Jun 5. Lancet. 2024. PMID: 38851202 No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Tap WD, et al. Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19. Lancet. 2019. PMID: 31229240 Free PMC article. Clinical Trial.
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, Bernthal NM, López Pousa A, Razak AA, Italiano A, Ahmed M, Le Cesne A, Tinoco G, Boye K, Martín-Broto J, Palmerini E, Tafuto S, Pratap S, Powers BC, Reichardt P, Casado Herráez A, Rutkowski P, Tait C, Zarins F, Harrow B, Sharma MG, Ruiz-Soto R, Sherman ML, Blay JY, Tap WD; MOTION investigators. Gelderblom H, et al. Lancet. 2024 Jun 22;403(10445):2709-2719. doi: 10.1016/S0140-6736(24)00885-7. Epub 2024 Jun 3. Lancet. 2024. PMID: 38843860 Free PMC article. Clinical Trial.

References

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Vimseltinib for tenosynovial giant cell tumour

Affiliations

Vimseltinib for tenosynovial giant cell tumour

Authors

Affiliations

Erratum in

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources